| Literature DB >> 35478078 |
Sarah Ziegler1, Alessia Raineri2, Vasileios Nittas2, Natalie Rangelov3, Fabian Vollrath3, Chantal Britt4, Milo A Puhan2.
Abstract
BACKGROUND: Long-term health consequences following acute SARS-CoV-2 infection, referred to as post-COVID-19 condition or Long COVID, are increasing, with population-based prevalence estimates for adults at around 20%. Persons affected by Long COVID report various health problems, yet evidence to guide clinical decision making remains scarce.Entities:
Mesh:
Year: 2022 PMID: 35478078 PMCID: PMC9046008 DOI: 10.1007/s40271-022-00579-7
Source DB: PubMed Journal: Patient ISSN: 1178-1653 Impact factor: 3.481
Fig. 1Process and development of a citizen-driven research project to develop research priorities most important to persons affected by Long COVID
Fig. 2Overview of the research themes and subcategories identified by the Long COVID Citizen Science Board
Baseline characteristics of 241 people participating in the online survey on the level of importance of 68 research questions about Long COVID. Figures are percentages and (numbers) unless otherwise stated
| Characteristics and category | % ( |
|---|---|
| Age, mean (SD) | 46.2 (12.3) |
| Sex | |
| Female | 83.8 (202) |
| Male | 16.2 (39) |
| Persons affected by Long COVID | 85.5 (206) |
| Relatives of patients with Long COVID | 7.1 (17) |
| Patients with ME/CFS | 14.5 (35) |
CFS chronic fatigue syndrome, ME myalgic encephalomyelitis, SD standard deviation
Baseline characteristics extracted from the online survey conducted between June and September 2021. The link to the online survey was shared with the Long COVID Working Group, Altea Long COVID Network platform and Long Covid Switzerland’s Facebook group
Results from an online survey (June–September 2021) on the level of importance of 68 research questions about Long COVID
| Research questions | Importance scorea | ||
|---|---|---|---|
| Mean (SD) | Median | ||
| A5.1 | What existing and new therapeutic approaches/treatment methods, depending on diagnosis and severity, are effective to treat Long COVID patients? | 4.86 (0.41) | 5 |
| A5.4 | What rehabilitation methods are effective for Long COVID? | 4.79 (0.51) | 5 |
| A5.7 | How can affected persons be supported in dealing with Long COVID? | 4.66 (0.65) | 5 |
| A5.3 | What therapies/treatments can improve or maintain memory performance in Long COVID patients? | 4.64 (0.64) | 5 |
| A4.4 | What are secondary diseases of Long COVID? | 4.60 (0.64) | 5 |
| A5.5 | What can different treatment methods look like in the course of Long COVID disease? | 4.58 (0.64) | 5 |
| A4.3 | What factors predict the course (improvement, relapse) of Long COVID? | 4.40 (0.77) | 5 |
| A2.1 | Through what processes does chronic fatigue syndrome develop in those affected by Long COVID? | 4.39 (0.83) | 5 |
| A4.1 | Which parameters can be used to describe the course of Long COVID? | 4.21 (0.73) | 4 |
| A3.2 | What clinical criteria can be used to diagnose Long COVID (even without a positive PCR, antigen or antibody test)? | 4.28 (0.87) | 4 |
| A6.1 | Does vaccination relieve Long COVID symptoms? | 4.30 (0.89) | 5 |
| A5.6 | How effective are coping and pacing methods for treating Long COVID patients? | 4.25 (0.85) | 4 |
| A3.1 | How should Long COVID be defined? | 4.24 (0.88) | 4 |
| A4.6 | How does Long COVID affect the psyche? | 4.23 (0.90) | 4 |
| A3.12 | What criteria must be met for Long COVID to be considered a chronic disease? | 4.20 (0.90) | 4 |
| A3.6 | Which autoantibodies are specific for Long COVID? | 4.19 (0.91) | 4 |
| A3.9 | How is Long COVID different from psychosomatic illness? | 4.29 (1.02) | 5 |
| A4.5 | What parameters can be used to classify the severity of Long COVID disease? | 4.09 (0.89) | 4 |
| A5.8 | How does occupational therapy affect the symptoms of Long COVID? | 4.10 (0.92) | 4 |
| A6.2 | Does vaccination protect against Long COVID? | 4.10 (1.06) | 4 |
| A3.11 | Which existing chronic fatigue syndrome questionnaires can be applied to Long COVID? | 3.90 (0.91) | 4 |
| A1.2 | What examinations, tests or measurements provide evidence of subsequent Long COVID disease? | 3.96 (1.06) | 4 |
| A4.7 | Is one protected from re-infection whilst one has Long COVID symptoms? | 4.05 (1.17) | 4 |
| A3.10 | Does Long COVID have a psychosomatic component? | 3.87 (1.17) | 4 |
| A3.5 | Do antibody test results differ between Long COVID-affected and COVID patients without long-term sequelae and asymptomatic positive tested patients? | 3.76 (1.08) | 4 |
| A1.1 | What factors increase the risk of developing Long COVID? | 3.80 (1.13) | 4 |
| A3.7 | How to distinguish Long COVID from post-acute COVID based on clinical criteria? | 3.71 (1.11) | 4 |
| A5.2 | Are there different treatment approaches for women and men? | 3.63 (1.12) | 4 |
| A3.8 | How can Long COVID be temporally differentiated from post-acute COVID? | 3.61 (1.11) | 4 |
| A3.4 | Are antibody tests a meaningful test method for COVID and indirectly for subsequent diagnosis of Long COVID? | 3.54 (1.15) | 4 |
| A4.2 | Does the course of Long COVID differ between women and men? | 3.42 (1.14) | 4 |
| A3.3 | Are there differences in diagnostic criteria between men and women? | 3.41 (1.16) | 4 |
| B3.1 | What cross-disciplinary/multidisciplinary services for diagnosis, treatment and rehabilitation are needed? | 4.59 (0.64) | 5 |
| B4.7 | How can healthcare professionals be made aware of chronic fatigue syndrome? | 4.46 (0.71) | 5 |
| B1.2 | Where are the main problems in diagnosis and prognosis? | 4.47 (0.75) | 5 |
| B2.3 | How can processes of care be regulated more efficiently? | 4.49 (0.78) | 5 |
| B4.5 | What knowledge exists among healthcare professionals regarding Long COVID? | 4.50 (0.82) | 5 |
| B4.2 | In which areas do professionals need support/advice? | 4.43 (0.77) | 5 |
| B4.1 | What training offers can be used to raise awareness and provide continuing education/training for healthcare professionals? | 4.45 (0.80) | 5 |
| B4.6 | How can research into chronic fatigue syndrome CFS be promoted by specialists? | 4.39 (0.80) | 5 |
| B2.4 | How can continuity of care be ensured? | 4.34 (0.82) | 5 |
| B3.3 | How can socially disadvantaged groups be reached and supported so that they receive the care they need? | 4.34 (0.83) | 5 |
| B4.4 | What structures/tools/facilities are needed so that professionals (physicians, therapists, service providers, product providers) can better network for diagnosis, treatment and rehabilitation? | 4.28 (0.85) | 4 |
| B2.5 | Where are the problematic interfaces between diagnosis, treatment, rehabilitation and follow-up in hospitalised and non-hospitalised patients? | 4.27 (0.87) | 4 |
| B1.4 | What signs should COVID patients see a doctor for, even before they may have Long COVID? | 4.15 (0.92) | 4 |
| B3.2 | How can peer support structures as well as the personal environment effectively support those affected? | 4.14 (0.94) | 4 |
| B1.1 | What different diagnostic methods and treatments do primary care physicians use? | 4.16 (0.99) | 4 |
| B1.5 | Are there differences in the diagnostic process between men and women? | 4.08 (0.98) | 4 |
| B2.1 | In what areas do affected people need physical services/products? | 4.08 (0.98) | 4 |
| B4.3 | What training opportunities do physicians need to better grasp the role of psychosomatics in chronic disease? | 4.05 (1.05) | 4 |
| B1.3 | At what point should COVID patients, even before they may have Long COVID, see a doctor? | 3.95 (1.01) | 4 |
| B2.2 | How many different doctors and/or therapists do Long COVID patients consult? | 3.77 (1.07) | 4 |
| C1.1 | What is the acceptance of Long COVID patients in work and everyday life? | 4.64 (0.70) | 5 |
| C2.1 | Which programmes can help Long COVID patients to cope with everyday working life or to make the best possible re-entry into working life? | 4.58 (0.70) | 5 |
| C1.4 | How can potential stigmatisation of those affected by Long COVID be prevented? | 4.33 (0.85) | 4 |
| C2.2 | What are the socioeconomic consequences of Long COVID? | 4.28 (0.83) | 4 |
| C1.2 | What is the attitude of health professionals toward Long COVID? | 4.28 (0.98) | 5 |
| C2.4 | How can socioeconomic consequences be reduced? | 4.09 (0.96) | 4 |
| C1.3 | How can potential stigmatisation of Long COVID patients be characterised? | 4.05 (0.96) | 4 |
| C2.3 | What are the socioeconomic costs of Long COVID? | 3.98 (1.00) | 4 |
| D1.4 | What are the consequences of Long COVID on the quality of life? | 4.62 (0.70) | 5 |
| D1.3 | Can Long COVID become chronic? | 4.58 (0.67) | 5 |
| D2.2 | What are secondary diseases of Long COVID in children? | 4.50 (0.71) | 5 |
| D2.3 | What are the consequences of Long COVID for children’s quality of life? | 4.49 (0.71) | 5 |
| D2.4 | Are the diagnosis and treatment of Long COVID the same in children/adolescents as in adults? | 4.37 (0.84) | 5 |
| D2.1 | How many children are affected by Long COVID? | 4.34 (0.82) | 4 |
| D1.1 | How many Long COVID cases do we have in Switzerland? | 4.15 (0.87) | 4 |
| D1.2 | Are there differences in prevalence between women and men? | 3.59 (1.04) | 4 |
SD standard deviation
aImportance score could range from 1 (not important) to 5 (very important)
A1: risk factors; A2: disease development; A3: definition and differential diagnosis; A4: prognosis; A5: treatment, rehabilitation and chronic care management; A6: vaccination; B1: availability of healthcare structures for diagnosis; B2: availability of interfaces for treatment continuity; B3: availability of healthcare structures; B4: awareness and knowledge among professionals; C1: acceptance and stigmatisation; C2: work and socioeconomic consequences; D1: prevalence of Long COVID among adults; D2: prevalence of Long COVID among children and adolescents
Fig. 3a Results of the online survey with 241 participants (June–September 2021) on the level of importance of the 68 research questions identified by the Long COVID Citizen Science Board. Individual research questions are plotted by their average level of importance, with a range from 1 (not important) to 5 (very important) (y-axis) and standard deviation (x-axis). b Results of the online voting on research priorities of the Long COVID Citizen Science Board. The circles refer to the research priorities of the Long COVID Citizen Science Board identified during the third meeting (October 2021)
| For persons affected by Long COVID, being diagnosed in a timely and correct manner seemed to be one of the biggest challenges. In addition to a clear diagnosis, those affected by Long COVID are currently missing adequate treatment options and access to adequate care that meets their multi-dimensional needs. |
| Research priorities most important to persons affected by Long COVID were “treatment, rehabilitation and chronic care management”, “availability of interfaces for treatment continuity”, “availability of healthcare structures”, “awareness and knowledge among professionals” and “prevalence of Long COVID in children and adolescents”. |
| The five identified research priorities may guide and justify future funding allocation and serve as a model for a new framework for patient-centred citizen-driven research agendas. |